^
Association details:
| Biomarker: | RAS wild-type + BRAF wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | futuximab/modotuximab (S95026) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P-105 COLSTAR study: Safety data on the first cohort of patients from the safety lead-in part of the study
Published date:
06/27/2023
Excerpt:
COLSTAR is a randomized, open-label study comparing Fu/Mo combined with TT to TT monotherapy in RAS/BRAFwt mCRC patients previously treated with chemotherapy….Among the patients included in the study, 4 out of 7 patients had stable disease (SD) as the best overall response (BOR)....Overall, the combination of Fu/Mo with TT was well tolerated in this cohort of 7 patients and no new safety signals were observed.
Secondary therapy:
trifluridine/tipiracil
DOI:
10.1016/j.annonc.2023.04.161
Trial ID:
